Focusing on cancers and autoimmune diseases
Fapon Biopharma is dedicated to the R&D of biologics for cancers and auto immune diseases treatment. Our pipeline includes 15 innovative projects covering multiple synergistic mechanisms.
FP008 is a fusion protein integrating an anti-PD-1 antibody and an IL-10M.
FP008 is a bifunctional anti-PD-1 x IL-10M fusion protein that can block the interaction between PD-1 and PD-L1, and reverse CD8+ T cell exhaustion by enriching IL-10M through PD-1 engagement, exerting synergistic anti-tumor activity of anti-PD-1 and IL-10.
FP008 function on exhausted T cells: A: FP008 showed significantly lower activity than wild-type IL-10 in IL-10R-STAT3 reporter gene assay. When FP008 was cross-linked with PD-1, the IL-10 activity was significantly enhanced. After repeated stimulation, T cells were induced into exhausted T cells. FP008 significantly reduced the apoptosis of exhausted T cells (B) and promoted IFN-γ secretion (C).
In vivo efficacy of FP008: FP008 surrogate showed significant anti-tumor efficacy in MC38 (A) and CT26 (B) mice models. After drug administration, the proportion of tumor infiltrating CD8+ T cells were significantly increased, while Treg cells were significantly decreased (C). In the humanized CT26 mouse model, FP008 showed better anti-tumor efficacy than Keytruda under low dose conditions (D). FP008 showed dose dependent inhibition on tumor growth and better efficacy than Keytruda (E).
Summary:
FP008 is a novel anti-PD-1×IL-10M fusion protein.
FP008 can effectively reduce the apoptosis of exhausted CD8+ T cells and activate T cells in in-vitro studies.
FP008 significantly increases the proportion of tumor-infiltrating CD8+ T cells and enhances anti-tumor activity in in vivo tumor models.
FP008 demonstrates a great safety profile.
